Profile of rheumatology patients willing to report adverse drug reactions: bias from selective reporting
Authors Protic D, VujasinoviÄ Stupar N, Bukumiric Z, Pavlov DolijanoviÄ S, Baltic S, MutavdÅ¾in S, MarkoviÄ-DeniÄ L, Zdravkovic M, TodoroviÄ Z
Received 15 September 2015
Accepted for publication 11 December 2015
Published 2 February 2016 Volume 2016:10 Pages 115—121
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Doris Leung
Peer reviewer comments 2
Editor who approved publication: Dr Johnny Chen
Dragana ProtiÄ,1 Nada VujasinoviÄ-Stupar,2 Zoran BukumiriÄ,3 Slavica Pavlov-DolijanoviÄ,4 SneÅ¾ana BaltiÄ,5 Slavica MutavdÅ¾in,6 Ljiljana Markovic-DeniÄ,7 Marija ZdravkoviÄ,8 Zoran TodoroviÄ1
1Department of Pharmacology, Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Belgrade, Belgrade, Serbia; 2Department 2, Institute of Rheumatology, Faculty of Medicine, University of Belgrade, Belgrade, Serbia; 3Institute for Medical Statistics and Informatics, Faculty of Medicine, University of Belgrade, Belgrade, Serbia; 4Department 5, Institute of Rheumatology, Faculty of Medicine, University of Belgrade, Belgrade, Serbia; 5Department 5, Institute of Rheumatology, Belgrade, Serbia; 6Institute of Physiology “Rihard Burjan”, Faculty of Medicine, University of Belgrade, Belgrade, Serbia; 7Institute of Epidemiology, Faculty of Medicine, University of Belgrade, Belgrade, Serbia; 8Department of Cardiology, Medical Center “BeÅ¾anijska kosa”, Faculty of Medicine, University of Belgrade, Belgrade, Serbia
Background: Adverse drug reactions (ADRs) have a significant impact on human health and health care costs. The aims of our study were to determine the profile of rheumatology patients willing to report ADRs and to identify bias in such a reporting system.
Methods: Semi-intensive ADRs reporting system was used in our study. Patients willing to participate (N=261) completed the questionnaire designed for the purpose of the study at the hospital admission. They were subsequently classified into two groups according to their ability to identify whether they had experienced ADRs during the previous month. Group 1 included 214 out of 261 patients who were able to identify ADRs, and group 2 consisted of 43 out of 261 patients who were not able to identify ADRs in their recent medical history.
Results: Group 1 patients were more significantly aware of their diagnosis than the patients from group 2. Marginal significance was found between rheumatology patients with and without neurological comorbidities regarding their awareness of ADRs. The majority of patients reported ADRs of cytotoxic drugs. The most reported ADRs were moderate gastrointestinal discomforts.
Conclusion: We may draw a profile of rheumatological patients willing to report ADRs: 1) The majority of them suffer from systemic inflammatory diseases and are slightly more prone to neurological comorbidities. 2) They are predominantly aware of their diagnosis but less able to identify the drugs that may cause their ADRs. 3) They tend to report mainly moderate gastrointestinal ADRs; that is, other cohorts of patients and other types of ADRs remain mainly undetected in such a reporting, which could represent a bias. Counseling and education of patients as well as developing a network for online communication might improve patients’ reporting of potential ADRs.
Keywords: adverse drug reactions, patient reporting system, rheumatology, bias
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]